Document and Entity Information - USD ($) $ in Millions	12 Months Ended
Document and Entity Information - USD ($) $ in Millions	Jun. 30, 2017	Sep. 01, 2017	Dec. 31, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	Lifevantage Corp
Entity Central Index Key	0000849146
Document Type	10-K
Document Period End Date	Jun. 30, 2017
Amendment Flag	false
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--06-30
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float			$ 114.5
Entity Common Stock, Shares Outstanding		14,228,144

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2017	Jun. 30, 2016
Current assets
Cash and cash equivalents	$ 11,458	$ 7,883
Accounts receivable	1,334	1,552
Income tax receivable	913	0
Inventory, net	16,575	25,116
Current deferred income tax asset		2,260
Prepaid expenses and deposits	5,266	6,301
Total current assets	35,546	43,112
Long-term assets
Property and equipment, net	3,127	3,456
Intangible assets, net	1,247	1,744
Long-term deferred income tax asset	4,087
Long-term deferred income tax asset		1,023
Other long-term assets	1,242	1,520
TOTAL ASSETS	45,249	50,855
Current liabilities
Accounts payable	4,850	8,891
Commissions payable	6,837	7,719
Income tax payable	215	3,284
Other accrued expenses	9,453	8,734
Current portion of long-term debt	2,000	2,000
Total current liabilities	23,355	30,628
Long-term debt
Principal amount	5,500	7,500
Less: unamortized discount and deferred offering costs	(60)	(91)
Long-term debt, net of unamortized discount and deferred offering costs	5,440	7,409
Other long-term liabilities	1,927	2,169
Total liabilities	30,722	40,206
Commitments and contingencies — Note 11
Stockholders’ equity
Preferred stock — par value $0.001, 50,000 shares authorized, no shares issued or outstanding	0	0
Common stock — par value $0.001, 250,000 shares authorized and 14,232 and 14,028 issued and outstanding as of June 30, 2017 and 2016, respectively	14	14
Additional paid-in capital	121,599	119,242
Accumulated deficit	(106,992)	(108,600)
Accumulated other comprehensive loss	(94)	(7)
Total stockholders’ equity	14,527	10,649
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 45,249	$ 50,855

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2017	Jun. 30, 2016
Statement of Financial Position [Abstract]
Preferred stock, par value (dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	50,000,000	50,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	250,000,000	250,000,000
Common stock, shares issued (in shares)	14,232,000	14,028,000
Common stock, shares outstanding (in shares)	14,232,000	14,028,000

Consolidated Statements of Operations and Comprehensive Income - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Income Statement [Abstract]
Revenue, net	$ 199,489	$ 206,540	$ 190,336
Cost of sales	33,456	33,932	28,010
Gross profit	166,033	172,608	162,326
Operating expenses:
Commissions and incentives	96,662	103,120	91,074
Selling, general and administrative	64,922	56,074	57,353
Total operating expenses	161,584	159,194	148,427
Operating income	4,449	13,414	13,899
Other expense:
Interest expense	(570)	(3,321)	(3,087)
Other expense, net	(969)	(1,409)	(159)
Total other expense	(1,539)	(4,730)	(3,246)
Income before income taxes	2,910	8,684	10,653
Income tax expense	(1,302)	(2,578)	(3,528)
Net income	$ 1,608	$ 6,106	$ 7,125
Net income per share:
Net income per share, basic (dollars per share)	$ 0.12	$ 0.44	$ 0.51
Net income per share, diluted (dollars per share)	$ 0.11	$ 0.42	$ 0.50
Weighted-average shares outstanding:
Basic (in shares)	13,881	13,730	13,899
Diluted (in shares)	14,118	14,531	14,150
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustment	$ (87)	$ 244	$ (135)
Other comprehensive income (loss), net of tax:	(87)	244	(135)
Comprehensive income	$ 1,521	$ 6,350	$ 6,990

Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)
Beginning balances, shares at Jun. 30, 2014		14,601
Beginning balances at Jun. 30, 2014	$ 2,333	$ 15	$ 114,423	$ (111,989)	$ (116)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	1,737		1,737
Exercise of options and warrants, shares		376
Exercise of options and warrants	589		589
Issuance of shares related to restricted stock, shares		189
Issuance of shares related to restricted stock	0
Shares canceled or surrendered as payment of tax withholding, shares		(129)
Repurchase of company stock, shares		(1,079)
Repurchase of company stock	(9,843)	$ (1)		(9,842)
Currency translation adjustment	(135)				(135)
Net income	7,125			7,125
Ending balances, shares at Jun. 30, 2015		13,958
Ending balances at Jun. 30, 2015	1,806	$ 14	116,749	(114,706)	(251)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	1,966		1,966
Exercise of options and warrants, shares		52
Exercise of options and warrants	527		527
Issuance of shares related to restricted stock, shares		76
Issuance of shares related to restricted stock	0
Shares canceled or surrendered as payment of tax withholding, shares		(58)
Currency translation adjustment	244				244
Net income	6,106			6,106
Ending balances, shares at Jun. 30, 2016		14,028
Ending balances at Jun. 30, 2016	10,649	$ 14	119,242	(108,600)	(7)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	2,315		2,315
Exercise of options and warrants, shares		76
Exercise of options and warrants	42		42
Issuance of shares related to restricted stock, shares		166
Issuance of shares related to restricted stock	0
Shares canceled or surrendered as payment of tax withholding, shares		(38)
Currency translation adjustment	(87)				(87)
Net income	1,608			1,608
Ending balances, shares at Jun. 30, 2017		14,232
Ending balances at Jun. 30, 2017	$ 14,527	$ 14	$ 121,599	$ (106,992)	$ (94)

Consolidated Statements of Cash Flows - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Cash Flows from Operating Activities:
Net income	$ 1,608	$ 6,106	$ 7,125
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	1,643	1,895	2,285
Loss on disposal of fixed assets	0	1,186	0
Stock-based compensation	2,647	2,621	1,806
Amortization of deferred financing fees	12	232	255
Amortization of debt discount	19	183	198
Write-off of capitalized debt transaction costs pursuant to debt refinance	0	1,544	0
Write-off of intangible assets	350	0	0
Deferred income tax	(740)	(2,118)	(796)
Changes in operating assets and liabilities:
Accounts receivable	160	(409)	149
Income tax receivable	(912)	2,179	2,502
Inventory, net	8,309	(15,650)	(936)
Prepaid expenses and deposits	3,318	(356)	1,269
Other long-term assets	103	258	826
Accounts payable	(6,210)	3,673	(171)
Income tax payable	(3,132)	1,481	966
Other accrued expenses	135	2,243	(2,170)
Other long-term liabilities	(713)	968	(87)
Net Cash Provided by Operating Activities	6,597	6,036	13,221
Cash Flows from Investing Activities:
Purchase of equipment	(1,055)	(562)	(1,159)
Net Cash Used in Investing Activities	(1,055)	(562)	(1,159)
Cash Flows from Financing Activities:
Proceeds from term loan	0	10,000	0
Payment of deferred financing fees	0	(99)	0
Excess tax benefits from stock-based compensation	0	266	128
Repurchase of company stock	0	0	(9,850)
Payment on term loan	(2,000)	(22,125)	(9,200)
Exercise of options and warrants	42	261	468
Net Cash Used in Financing Activities	(1,958)	(11,697)	(18,454)
Foreign Currency Effect on cash	(9)	201	(90)
Increase (decrease) in cash and cash equivalents	3,575	(6,022)	(6,482)
Cash and Cash Equivalents — beginning of period	7,883	13,905	20,387
Cash and Cash Equivalents — end of period	11,458	7,883	13,905
Non Cash Investing and Financing Activities:
Increase in property and equipment/other long-term liabilities	116	0	0
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for interest	438	1,342	2,633
Cash paid for income taxes	$ 5,496	$ 1,368	$ 1,658
Common stock shares issued upon cashless warrant exercises	53	6	252
Total cashless exercise price of warrants	$ 88	$ 9	$ 1,462
Gross warrants underlying cashless exercises	63	6	418

The Company	12 Months Ended
The Company	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company	The Company LifeVantage Corporation (the "Company") is a company focused on nutrigenomics, the study of how nutrition and naturally occurring compounds affect our genes. The Company is dedicated to helping people achieve their health, wellness and financial independence goals. The Company provides quality, scientifically-validated products and a financially rewarding direct sales business opportunity to preferred customers, retail customers and independent distributors who seek a healthy lifestyle and financial freedom. The Company sells its products in the United States, Japan, Hong Kong, Australia, Canada, Mexico, Thailand, the United Kingdom and the Netherlands. The Company engages in the identification, research, development and distribution of advanced nutraceutical dietary supplements and skin care products, including Protandim^®, its line of scientifically-validated dietary supplements, TrueScience^®, its line of anti-aging skin care products, Petandim^™ for Dogs, its companion pet supplement formulated to combat oxidative stress in dogs, Axio^®, its Smart Energy Drink mixes, and PhysIQ^™, its Smart Weight Management System. The Company was incorporated in Colorado in June 1988 under the name Andraplex Corporation. The Company changed its corporate name to Yaak River Resources, Inc. in January 1992, and subsequently changed it again in October 2004 to Lifeline Therapeutics, Inc. In October 2004 and March 2005, the Company acquired all of the outstanding common stock of Lifeline Nutraceuticals Corporation. In November 2006, the Company changed its name to LifeVantage Corporation.

Summary of Significant Accounting Policies

12 Months Ended

Jun. 30, 2017

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Revision of Previously Issued Financial Statements for Correction of Immaterial Errors

During the preparation of our fiscal 2017 tax provision, management discovered immaterial errors regarding foreign book-to-tax differences and the reconciliation of balance sheet accounts impacted by the income tax provision.

Pursuant to the guidance of SEC Staff Accounting Bulletin (“SAB”) No. 99, Materiality, management concluded that the errors were not material to any of the Company's prior period financial statements. Although the errors were immaterial to prior periods, the prior period financial statements were revised, in accordance with SAB No. 108, Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements. Prior period amounts stated in this Form 10-K have been revised to facilitate comparability between current and prior year periods.

The following tables summarize the impact and financial statement line items affected by the revisions:



	As of June 30, 2016 (in thousands)
Consolidated Balance Sheet:	As Reported			Adjustments			As Revised
Current deferred income tax asset	$	2,776		$	(516	)	$	2,260
Prepaid expenses and deposits	5,082			1,219			6,301
Total current assets	42,409			703			43,112
Long-term deferred income tax asset	1,130			(107		)	1,023
Total assets	50,259			596			50,855
Income tax payable	1,206			2,078			3,284
Total current liabilities	28,550			2,078			30,628
Total liabilities	38,128			2,078			40,206
Additional paid-in capital	120,150			(908		)	119,242
Accumulated deficit	(108,076		)	(524		)	(108,600		)
Accumulated other comprehensive income (loss)	43			(50		)	(7		)
Total stockholders’ equity	12,131			(1,482		)	10,649
Total liabilities and stockholders' equity	50,259			596			50,855



	For the year ended June 30, 2016 (in thousands, except per share data)
Statement of Operations and Comprehensive Income:	As Reported			Adjustments			As Revised
Income tax expense	$	(2,665	)	$	87		$	(2,578	)
Net income	6,019			87			6,106
Net income per share:
Basic	0.44						0.44
Diluted	0.41						0.42
Foreign currency translation adjustment	294			(50		)	244
Other comprehensive income (loss), net of tax:	294			(50		)	244
Comprehensive income	6,313			37			6,350



	For the year ended June 30, 2015 (in thousands, except per share data)
Statement of Operations and Comprehensive Income:	As Reported			Adjustments		As Revised
Income tax expense	$	(3,666	)	$	138	$	(3,528	)
Net income	6,987			$	138	$	7,125
Net income per share:
Basic	0.50					$	0.51
Diluted	0.49					$	0.50
Comprehensive income	6,852			$	138	$	6,990



	Statements of Stockholders' Equity
	Common Stock			Additional Paid-In Capital			Accumulated Deficit			Accumulated Other Comprehensive Income (Loss)			Total
(In thousands)	Shares	Amount		Additional Paid-In Capital			Accumulated Deficit			Accumulated Other Comprehensive Income (Loss)			Total
Balances, June 30, 2014, as reported	14,601	$	15	$	115,331		$	(111,240	)	$	(116	)	$	3,990
Adjustments	—	—		(908		)	(749		)	—			(1,657		)
Balances, June 30, 2014, as revised	14,601	$	15	$	114,423		$	(111,989	)	$	(116	)	$	2,333

Balances, June 30, 2015, as reported	13,958	$	14	$	117,657		$	(114,095	)	$	(251	)	$	3,325
Adjustments	—	—		(908		)	(611		)	—			(1,519		)
Balances, June 30, 2015, as revised	13,958	$	14	$	116,749		$	(114,706	)	$	(251	)	$	1,806

Balances, June 30, 2016, as reported	14,028	$	14	$	120,150		$	(108,076	)	$	43		$	12,131
Adjustments	—	—		(908		)	(524		)	(50		)	(1,482		)
Balances, June 30, 2016, as revised	14,028	$	14	$	119,242		$	(108,600	)	$	(7	)	$	10,649



	For the year ended June 30, 2016 (in thousands)
Consolidated Statement of Cash Flows	As Reported			Adjustments			As Revised
Cash Flows from Operating Activities:
Net income	$	6,019		$	87		$	6,106
Deferred income tax	(2,491		)	373			(2,118		)
Prepaid expenses and deposits	392			(748		)	(356		)
Income tax payable	1,143			338			1,481
Net Cash Provided by Operating Activities	5,986			50			6,036
Foreign Currency Effect on cash	251			(50		)	201
Increase (decrease) in cash and cash equivalents	(6,022		)	—			(6,022		)



	For the year ended June 30, 2015 (in thousands)
	As Reported			Adjustments			As Revised
Cash Flows from Operating Activities:
Net income	$	6,987		$	138		$	7,125
Deferred income tax	91			(887		)	(796		)
Prepaid expenses and deposits	1,486			(217		)	1,269
Income tax payable	—			966			966
Net Cash Provided by Operating Activities	13,221			—			13,221
Increase (decrease) in cash and cash equivalents	(6,482		)	—			(6,482		)

Consolidation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions are eliminated in consolidation. Certain other prior period balances have also been reclassified to conform to the current period presentation.

Use of Estimates

The Company prepares the consolidated financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America (GAAP). In preparing these statements, the Company is required to use estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates and assumptions. On an ongoing basis, the Company reviews its estimates, including those related to inventory valuation and obsolescence, sales returns, income taxes and tax valuation reserves, share-based compensation, and loss contingencies.

Foreign Currency Translation

A portion of the Company’s business operations occurs outside the United States. The local currency of each of the Company’s subsidiaries is generally its functional currency. All assets and liabilities are translated into U.S. Dollars at exchange rates existing at the balance sheet dates, revenue and expenses are translated at weighted-average exchange rates and stockholders’ equity is recorded at historical exchange rates. The resulting foreign currency translation adjustments are recorded as a separate component of stockholders’ equity in the consolidated balance sheets and as a component of comprehensive income. Transaction gains and losses are included in other expense, net in the consolidated statements of operations and comprehensive income.

Fair Value of Financial Instruments

Accounting guidance on fair value measurements and disclosures requires disclosures about the fair value for all financial instruments, whether or not recognized, for financial statement purposes. Disclosures about fair value of financial instruments are based on pertinent information available to management as of June 30, 2017 and 2016. Accordingly, the estimates presented in these consolidated financial statements are not necessarily indicative of the amounts that could be realized on disposition of the financial instruments.

Management has estimated the fair values of cash and cash equivalents, accounts receivable, accounts payable, commissions payable and other accrued expenses to approximate their respective carrying values reported in these consolidated financial statements because of their short maturities.

Cash and Cash Equivalents

The Company considers only its monetary liquid assets with original maturities of three months or less to be cash and cash equivalents.

Accounts Receivable

The Company’s accounts receivable for the years ended June 30, 2017 and 2016 consist primarily of credit card receivables. Based on the Company’s verification process for customer credit cards and historical information available, management has determined that an allowance for doubtful accounts on credit card sales related to its customer sales as of June 30, 2017 or 2016 is not necessary. No bad debt expense has been recorded for the years ended June 30, 2017, 2016 and 2015.

Inventory

As of June 30, 2017 and 2016, inventory consisted of (in thousands):



	June 30,
	2017		2016
Finished goods	$	7,817	$	14,852
Raw materials	8,758		10,264
Total inventory	$	16,575	$	25,116

Inventories are carried and depicted above at the lower of cost or market, using the first-in, first-out method, which includes a reduction in inventory values of $0.9 million and $0.4 million at June 30, 2017 and 2016, respectively, related to obsolete and slow-moving inventory.

Property and Equipment

Property and equipment are recorded at cost and depreciated using the straight-line method over the following useful lives:



	Years
Equipment (includes computer hardware and software)	3
Furniture and fixtures	5
Vehicles	5

Leasehold improvements are depreciated over the shorter of estimated useful life of the related asset or the lease term.

The cost of normal maintenance and repairs is charged to expense as incurred. When an asset is sold or otherwise disposed of, the cost and associated accumulated depreciation are removed from the accounts and the resulting gain or loss is recognized in the consolidated statements of operations and comprehensive income in other expense, net. Significant expenditures that increase the useful life of an asset are capitalized and depreciated over the estimated useful life of the asset. Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. An impairment loss is recognized if the carrying amount of the asset exceeds its fair value. During the year ended June 30, 2017, there were no losses on disposal of assets. During the year ended June 30, 2016, the Company recognized a loss on disposal of $1.2 million related to the write-off of previously capitalized software development costs incurred.

Intangible Assets

Intangible assets are stated at cost less accumulated amortization. Definite-lived intangible assets are amortized over their related useful lives, using a straight-line method, consistent with the underlying expected future cash flows related to the specific intangible asset. Definite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances exist that indicate the carrying amount of an asset may not be recoverable. When indicators of impairment exist, an estimate of undiscounted net cash flows is used in measuring whether the carrying amount of the asset or related asset group is recoverable. Measurement of the amount of impairment, if any, is based upon the difference between the asset’s carrying value and estimated fair value.

Indefinite-lived intangible assets are not amortized; however, they are tested at least annually for impairment or more frequently if events or changes in circumstances exist that may indicate impairment. An impairment loss is recognized if the carrying amount of the asset exceeds its fair value. Annual impairment tests were completed resulting in no impairment charges for any of the periods shown. During the year ended June 30, 2017, the Company recognized a loss of $0.4 million upon write-off of previously capitalized indefinite-lived intangible assets.

Impairment of Long-Lived Assets

Pursuant to guidance established for impairment or disposal of assets, the Company assesses impairment whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset may not be recoverable. When an assessment for impairment of long-lived assets, long-lived assets to be disposed of, and certain identifiable intangibles related to those assets is performed, the Company is required to compare the net carrying value of long-lived assets on the lowest level at which cash flows can be determined on a consistent basis to the related estimates of future undiscounted net cash flows for such assets. If the net carrying value exceeds the net cash flows, then an impairment is recognized to reduce the carrying value to the estimated fair value, generally equal to the future discounted net cash flow. Except as previously disclosed, for the years ended June 30, 2017 and 2016, management has concluded that there are no indications of impairment.

Concentration of Credit Risk

Accounting guidance for financial instruments requires disclosure of significant concentrations of credit risk regardless of the degree of such risk. Financial instruments with significant credit risk include cash and cash equivalents. At June 30, 2017, the Company had $8.2 million in cash accounts at one financial institution and $3.3 million in other financial institutions. As of June 30, 2017 and 2016, and during the years then ended, the Company’s cash balances exceeded federally insured limits.

Revenue Recognition

The Company ships the majority of its product directly to the consumer and receives substantially all payment for these sales in the form of credit card receipts. Revenue from direct product sales to customers is recognized upon shipment, which is when passage of title and risk of loss occurs. Estimated returns are recorded when product is shipped. Subject to some exceptions based on local regulations, the Company’s return policy is to provide a full refund for product returned within 30 days if the returned product is unopened or defective. After 30 days, the Company generally does not issue refunds to direct sales customers for returned product. The Company allows terminating distributors to return up to 30% of unopened, unexpired product that they have purchased within the prior twelve months for a full refund, less a 10% restocking fee. The Company establishes the returns reserve based on historical experience. The returns reserve is evaluated on a quarterly basis. As of June 30, 2017 and 2016, the Company’s reserve balance for returns and allowances was $0.4 million and $0.3 million, respectively.

Commissions and Incentives

Commissions and incentives expenses are the Company’s most significant expenses and are classified as operating expenses. Commissions and incentives expenses include sales commissions paid to the Company's independent distributors, special incentives, costs for incentive trips and other rewards. Commissions and incentives expenses do not include any amounts the Company pays to its independent distributors for personal purchases. Commissions paid to independent distributors on personal purchases are considered a sales discount and are reported as a reduction to net revenue.

Shipping and Handling

Shipping and handling costs associated with inbound freight and freight out to customers, including independent distributors, are included in cost of sales. Shipping and handling fees charged to all customers are included in sales.

Research and Development Costs

The Company expenses all costs related to research and development activities as incurred. Research and development expenses for the years ended June 30, 2017, 2016 and 2015 were $1.1 million, $1.0 million and $2.4 million, respectively.

Stock-Based Compensation

The Company recognizes stock-based compensation by measuring the cost of services to be rendered based on the grant date fair value of the equity award. The Company recognizes stock-based compensation, net of any estimated forfeitures, over the period an employee is required to provide service in exchange for the award, generally referred to as the requisite service period. For awards with market-based performance conditions, the cost of the awards is recognized as the requisite service is rendered by employees, regardless of when, if ever, the market-based performance conditions are satisfied.

The Black-Scholes option pricing model is used to estimate the fair value of stock options. The determination of the fair value of stock options is affected by the Company's stock price and a number of assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. The Company uses historical volatility as the expected volatility assumption required in the Black-Scholes model. The Company utilizes a simplified method for estimating the expected life of the options. The Company uses this method because it believes that it provides a better estimate than the Company’s historical data as post vesting exercises have been limited. The risk-free interest rate assumption is based on observed interest rates appropriate for the expected terms of the stock options.

The fair value of restricted stock grants is based on the closing market price of the Company's stock on the date of grant less the Company's expected dividend yield. The fair value of performance restricted stock units that include market-based performance conditions is based on the closing market price of the Company's stock on the date of grant less the Company's expected dividend yield, with further adjustments made to reflect the market conditions that must be satisfied in order for the units to vest by using a Monte-Carlo simulation model. Key assumptions for the Monte-Carlo simulation model include the risk-free rate, expected volatility, expected dividends and the correlation coefficient. The fair value of cash-settled performance-based awards, accounted for as liabilities, is remeasured at the end of each reporting period and is based on the closing market price of the Company’s stock on the last day of the reporting period. The Company recognizes compensation costs for awards with performance conditions when it concludes it is probable that the performance conditions will be achieved. The Company reassesses the probability of vesting at each balance sheet date and adjusts compensation costs accordingly.

Reverse Stock Split

In October 2015, following approval of the Company's shareholders, the Company's board of directors approved the filing of an amendment to the Company's amended and restated articles of incorporation to effectuate a reverse split of the issued and outstanding shares of the Company's common stock on a one-for-seven basis. The reverse stock split was effective on October 19, 2015. The par value and authorized number of shares of common stock were not adjusted as a result of the reverse split. All fractional shares resulting from the reverse stock split were rounded up. All issued and outstanding common stock and per share amounts contained within the Company's consolidated financial statements and footnotes have been retroactively adjusted to reflect this reverse stock split for all periods presented.

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using statutory tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities from a change in tax rates is recognized in income in the period that includes the effective date of the change.

The Company recognizes tax liabilities or benefits from an uncertain position only if it is more likely than not that the position will be sustained upon examination by taxing authorities based on the technical merits of the issue. The amount recognized would be the largest liability or benefit that the Company believes has greater than a 50% likelihood of being realized upon settlement.

Income Per Share

Basic income per common share is computed by dividing the net income by the weighted-average number of common shares outstanding during the period, less unvested restricted stock awards. Diluted income per common share is computed by dividing net income by the weighted-average common shares and potentially dilutive common share equivalents using the treasury stock method.

The effects of approximately 0.2 million and 0.2 million common shares issuable upon exercise of options and non-vested shares of restricted stock outstanding as of June 30, 2017 and 2016, respectively, are not included in the computations as their effect was anti-dilutive.

The following is a reconciliation of net income per share and the weighted-average common shares outstanding for purposes of computing basic and diluted net income per share (in thousands, except per share amounts):



	Years ended June 30,
	2017		2016		2015
			(As revised)		(As revised)
Numerator:
Net income	$	1,608	$	6,106	$	7,125
Denominator:
Basic weighted-average common shares outstanding	13,881		13,730		13,899
Effect of dilutive securities:
Stock awards and options	237		735		180
Warrants	—		66		71
Diluted weighted-average common shares outstanding	14,118		14,531		14,150
Net income per share, basic	$	0.12	$	0.44	$	0.51
Net income per share, diluted	$	0.11	$	0.42	$	0.50

Segment Information

The Company operates in a single operating segment by selling products to an international network of independent distributors that operates in an integrated manner from market to market. Commissions and incentives expenses are the Company’s largest expense comprised of the commissions paid to its independent distributors. The Company manages its business primarily by managing its international network of independent distributors. The Company does not use profitability reports on a regional or divisional basis for making business decisions. However, the Company does report revenue in two geographic regions: the Americas region and the Asia/Pacific & Europe region. Revenues by geographic area are as follows (in thousands):



	Years ended June 30,
	2017		2016		2015
Americas	$	150,841	$	158,291	$	138,118
Asia/Pacific & Europe	48,648		48,249		52,218
Total revenues	$	199,489	$	206,540	$	190,336

Additional information as to the Company’s revenue from operations in the most significant geographical areas is set forth below (in thousands):



	Years ended June 30,
	2017		2016		2015
United States	$	144,842	$	152,830	$	132,831
Japan	$	39,390	$	36,343	$	41,428

As of June 30, 2017, long-lived assets were $6.2 million in the U.S. and $0.9 million in Japan. As of June 30, 2016, long-lived assets were $4.2 million in the U.S. and $1.3 million in Japan.

Major Products

The Company's revenues are largely attributed to two product lines, Protandim^® and TrueScience^®, which each accounted for more than 10% of total revenues for each of the years ended June 30, 2017, 2016 and 2015. On a combined basis, these products represent approximately 77.9%, 77.9% and 83.7% of the Company's worldwide gross revenues for the years ended June 30, 2017, 2016 and 2015, respectively. The following table shows revenues by major product line for the years ended June 30, 2017, 2016 and 2015.



	For the years ended June 30,
	2017				2016				2015
Protandim^®product line	$	130,873	65.6	%	$	128,019	62.0	%	$	120,967	63.6	%
TrueScience^®product line	24,440		12.3	%	32,914		15.9	%	38,287		20.1	%
Other	44,176		22.1	%	45,607		22.1	%	31,082		16.3	%
Total	$	199,489	100.0	%	$	206,540	100.0	%	$	190,336	100.0	%

New Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2014-09, Revenue from Contracts with Customers (Topic 606), and has subsequently issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, ASU 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net), ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, ASU 2016-11, Revenue Recognition (Topic 605) and Derivatives and Hedging (Topic 815), ASU 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, and ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers (collectively, Topic 606).

Topic 606 outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The core principle of the new guidance is for companies to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration it expects to receive in exchange for those goods or services. The guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract. This guidance is effective for the Company beginning on July 1, 2018 with the option to adopt using either a full retrospective or a modified retrospective approach. The Company expects to adopt Topic 606 using the modified retrospective approach, under which the cumulative effect of initially applying Topic 606 is recognized as an adjustment to the opening balance of retained earnings in the first quarter of fiscal 2019.

The Company is concluding the assessment phase of implementing this guidance. The Company has evaluated each of its revenue streams and has identified similar performance obligations under Topic 606 as compared to current revenue recognition guidance. As a result, the Company expects that the timing of the recognition of revenue will remain materially unchanged compared to the current guidance.

There are also considerations related to internal control over financial reporting associated with implementing Topic 606. The Company is currently evaluating its control framework for revenue recognition and identifying any changes that may need to be made in response to the new guidance. Disclosure requirements under Topic 606 have been expanded compared to the disclosure requirements under the current guidance. Designing and implementing the appropriate controls over gathering and reporting the information required under Topic 606 is currently in process.

In April 2015, FASB issued ASU 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. This guidance requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The Company adopted this updated standard in the current year during the interim period ended September 30, 2016 by reclassifying the debt issuance costs from long-term assets to a direct deduction from the related debt, consistent with the debt discount. All prior period balances have been retrospectively adjusted.

In November 2015, FASB issued ASU No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes. Current GAAP requires an entity to separate deferred income tax liabilities and assets into current and noncurrent amounts in a classified statement of financial position. To simplify the presentation of deferred income taxes, the amendments in this update require that all deferred tax assets or liabilities be classified as noncurrent in the classified statement of financial position. The Company early adopted this update prospectively during the first quarter of fiscal 2017, which resulted in the reclassification of the deferred taxes from current to noncurrent on the balance sheet. Prior period balances were not retrospectively adjusted.

In February 2016, FASB issued ASU No. 2016-02, Leases (Topic 841). For lessees, the amendments in this update require that for all leases not considered to be short term, a company recognize both a lease liability and right-of-use asset on its balance sheet, representing the obligation to make payments and the right to use or control the use of a specified asset for the lease term. The amendments in this update are effective for annual periods beginning after December 15, 2018 and interim periods within those annual periods. The Company is currently evaluating the impact that this amendment will have on its consolidated financial statements.

In March 2016, FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendments in this update involve several aspects of the accounting for share-based compensation transactions, including the income tax consequences, forfeitures, statutory withholding requirements and cash flow classification for applicable transactions, in an effort to reduce costs and complexity associated with these transactions while maintaining the usefulness of financial information. Prior to this update, all excess tax benefits were recognized in additional paid in capital ("APIC") and accumulated in an APIC pool and any tax deficiencies realized were offset against the APIC pool to the extent available, with any excess amounts recognized in the income statement. Under this new amendment, any excess tax benefits or deficiencies resulting from the exercise, vesting or settlement of share-based payment transactions will be recognized in the income statement as tax benefits or expenses prospectively from the date of adoption. Estimating forfeitures as part of the recognition of compensation costs is no longer required, rather, an entity can make the election to account for forfeitures when they occur. The Company early adopted this update during the first quarter of fiscal 2017 and began recording the excess tax benefits to the income statement. The Company elected to continue estimating forfeitures as part of its share-based compensation accounting policy.

In May 2017, FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. The amendments in this update provide guidance about which changes to the terms or conditions of a share-based award require an entity to apply modification accounting in Topic 718. An entity should account for the effects of a modification unless all the following are met: (1) The fair value of the modified award is the same as the fair value of the original award immediately before the original award is modified, (2) The vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified, (3) The classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. The current disclosure requirements in Topic 718 apply regardless of whether an entity is required to apply modification accounting under the amendments in this update. The amendments in this update are effective for all annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted. The amendments in this update should be applied prospectively to an award modified on or after the adoption date. The Company will apply this amendment to any award modifications made on or after the adoption date.

Property and Equipment, Net

12 Months Ended

Jun. 30, 2017

Property, Plant and Equipment [Abstract]

Property and Equipment, Net

Property and equipment, net consist of (in thousands):



	June 30,
	2017			2016
Equipment (includes computer hardware and software)	$	7,420		$	6,402
Furniture and fixtures	1,536			1,485
Leasehold improvements	3,421			3,497
Vehicles	51			51
Accumulated depreciation	(9,301		)	(7,979		)
Total property and equipment, net	$	3,127		$	3,456

Depreciation expense totaled $1.5 million, $1.8 million and $2.3 million for the years ended June 30, 2017, 2016 and 2015, respectively.

Long-Term Debt

12 Months Ended

Jun. 30, 2017

Debt Disclosure [Abstract]

Long-Term Debt

On October 18, 2013, the Company entered into a financing agreement providing for a term loan facility in an aggregate principal amount of $47 million (the “October 2013 Term Loan”) and a delayed draw term loan facility in an aggregate principal amount not to exceed $20 million (the “October 2013 Delayed Draw Term Loan”). The October 2013 Delayed Draw Term Loan was available for borrowing in specified minimum amounts from time to time beginning after the effective date until October 18, 2014. The Company did not borrow any amounts under the October 2013 Delayed Draw Term Loan.

On May 1, 2015, the Company entered into an Amendment No 1 to October 2013 Term Loan ("Amendment No. 1"). Amendment No. 1 revised the March 31, 2015 and June 30, 2015 consolidated EBITDA covenants from $20.6 million and $21.3 million, respectively, to $17.0 million for each quarter end. Amendment No. 1 also revised the minimum unrestricted cash and cash equivalents that the Company was required to hold from $10.0 million to $8.0 million for the reporting periods ended March 31, 2015 and June 30, 2015. In addition, Amendment No. 1 required that the Company make certain accelerated principal payments on the October 2013 Term Loan totaling $4.5 million during the fourth quarter of fiscal year 2016.

On August 27, 2015, the Company entered into an Amendment No. 2 to October 2013 Term Loan ("Amendment No. 2" and collectively, with the October 2013 Term Loan, as previously amended by Amendment No. 1, the "October 2013 Credit Facility"). Amendment No. 2 revised the covenants related to minimum consolidated EBITDA (as defined in the amended October 2013 Term Loan) for the four consecutive fiscal quarters ending September 30, 2015, December 31, 2015, March 31, 2016 and June 30, 2016 from $22.2 million, $23.1 million, $24.4 million and $25.6 million, respectively, to $14.5 million, $15.0 million, $17.0 million and $17.5 million, respectively. In addition, Amendment No. 2 required that the Company make additional monthly accelerated principal payments on the October 2013 Term Loan in the amount of $0.5 million commencing on October 15, 2015 and continuing until the October 2013 Term Loan was paid in full. Amendment No. 2 also required that the Company make additional accelerated payments at the end of each fiscal quarter in the amount of all unrestricted cash on hand as of the close of business on the last day of the quarter in excess of $12.5 million.

The principal amount of the October 2013 Term Loan was payable in consecutive quarterly installments beginning with the calendar quarter ended March 31, 2014 and matured on the earlier of October 18, 2018 or such date as the outstanding loans become payable in accordance with the terms of the October 2013 Term Loan (the “Final Maturity Date”). The October 2013 Term Loan bore interest at a rate equal to 7.50% per annum plus the greater of (i) 1.25% or (ii) LIBOR, or at the Company’s option, a reference rate (as defined in the October 2013 Term Loan) plus 6.50% per annum, with such interest payable monthly. On March 30, 2016, the Company repaid the full amount outstanding under the October 2013 Term Loan and terminated the October 2013 Credit Facility.

On March 30, 2016, the Company entered into a loan agreement (the "March 2016 Loan Agreement") to refinance its outstanding debt under the October 2013 Term Loan. In connection with the March 2016 Loan Agreement and on the same date, the Company entered into a security agreement (the "March 2016 Security Agreement"). The March 2016 Loan Agreement provides for a term loan in an aggregate principal amount of $10.0 million (the "March 2016 Term Loan") and a revolving loan facility in an aggregate principal amount not to exceed $2.0 million (the "March 2016 Revolving Loan," and collectively with the March 2016 Term Loan, the March 2016 Loan Agreement and the March 2016 Security Agreement, the "March 2016 Credit Facility").

The principal amount of the March 2016 Term Loan is payable in consecutive quarterly installments in the amount of $0.5 million plus accrued interest beginning with the fiscal quarter ended June 30, 2016 and maturing on March 30, 2019 (the "Maturity Date"). The March 2016 Term Loan bears interest at a fixed rate of 4.93%. If the Company borrows under the March 2016 Revolving Loan, interest will be payable quarterly in arrears on the last day of each fiscal quarter at a variable rate equal to the 30 day LIBOR rate plus 3.50%.

The Company’s obligations under the March 2016 Credit Facility are secured by a security interest in substantially all of the Company’s assets. Loans outstanding under the March 2016 Credit Facility may be prepaid in whole or in part at any time without premium or penalty. In addition, if, at any time, the aggregate principal amount outstanding under the March 2016 Revolving Loan exceeds $2.0 million, the Company must prepay an amount equal to such excess. Any principal amount of the March 2016 Term Loan which is prepaid or repaid may not be re-borrowed.

The March 2016 Credit Facility contains customary covenants, including affirmative and negative covenants that, among other things, restrict the Company's ability to create certain types of liens, incur additional indebtedness, declare or pay dividends on or redeem capital stock, make other payments to holders of equity interests in the Company, make certain investments, purchase or otherwise acquire all or substantially all the assets or equity interests of other companies, sell assets or enter into consolidations, mergers or transfers of all or any substantial part of the Company's assets. The March 2016 Credit Facility also contains various financial covenants that require the Company to maintain a certain consolidated minimum tangible net worth, minimum working capital amounts, and debt to EBITDA and fixed charge coverage ratios. Additionally, the March 2016 Credit Facility contains cross-default provisions, whereby a default under the terms of certain indebtedness or an uncured default of a payment or other material obligation of the Company under a material contract of the Company will cause a default on the remaining indebtedness under the March 2016 Credit Facility. As of June 30, 2017, the Company was in compliance with all applicable covenants under the March 2016 Credit Facility; provided, however, that on October 24, 2016, the Company was granted a waiver and extension to covenants requiring the Company to provide the lender with audited financial statements for the Company's 2016 fiscal year on or before October 28, 2016. Under the limited waiver and extension, the lender agreed to waive compliance with this requirement if the Company delivered such audited financial statements prior to December 31, 2016. In connection with filing the Company's FY 2016 Form 10-K on December 12, 2016, the Company delivered all required information to the lender to satisfy the requirement.

The Company incurred transaction costs associated with the October 2013 Credit Facility totaling $2.7 million. In connection with refinancing the outstanding debt under the October 2013 Credit Facility on March 30, 2016, the Company charged to interest expense the remaining $1.5 million in unamortized transaction costs associated with that credit facility. At June 30, 2017, the Company had unamortized transaction costs totaling $0.1 million included in the consolidated balance sheet related to the March 2016 Credit Facility. This balance will be amortized to interest expense using the interest method over the term of the loan.

The Company’s book value for the March 2016 Credit Facility approximates the fair value. Aggregate future principal payments required in accordance with the terms of the March 2016 Credit Facility are as follows (in thousands):



Year ending June 30,	Amount
2018	$	2,000
2019	5,500
	$	7,500

Stockholders' Equity	12 Months Ended
Stockholders' Equity	Jun. 30, 2017
Equity [Abstract]
Stockholders' Equity	Stockholders’ Equity During the years ended June 30, 2017, 2016 and 2015, the Company issued 0.1 million, 0.1 million and 0.4 million shares, respectively, of common stock as a result of the exercise of options and warrants and during the years ended June 30, 2017, 2016 and 2015, the Company issued 0.2 million, 0.1 million and 0.2 million shares, respectively, of restricted common stock. During the year ended June 30, 2017, 39,000 shares of restricted stock were canceled or surrendered as payment of tax withholding upon vesting. On November 6, 2014, the Company announced a share repurchase program authorizing it to repurchase up to $7 million in shares of the Company's common stock. As part of that repurchase program, the Company entered into a pre-arranged stock repurchase plan that operated in accordance with guidelines specified under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the "1934 Act"). The pre-arranged stock repurchase program terminated in accordance with its terms on February 13, 2015. Pursuant to the program, the Company purchased 0.6 million shares of its common stock at an aggregate purchase price of $5.9 million. The remaining $1.1 million authorized under the program for repurchases was unused when the program expired. On June 3, 2014, the Company announced a share repurchase program authorizing it to repurchase up to $4 million in shares of the Company's common stock. As part of that repurchase program, the Company entered into a pre-arranged stock repurchase plan that operated in accordance with guidelines specified under Rule 10b5-1 of the 1934 Act. The pre-arranged stock repurchase program terminated in accordance with its terms on December 31, 2014. Pursuant to the program, the Company purchased 0.4 million shares of its common stock at an aggregate purchase price of $4 million under this repurchase program. The Company’s Articles of Incorporation authorize the issuance of preferred shares. However, as of June 30, 2017, none have been issued nor have any rights or preferences been assigned to the preferred shares by the Company’s Board of Directors.

Share-Based Compensation

12 Months Ended

Jun. 30, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Share-Based Compensation

Long-Term Incentive Plans

The Company adopted and the shareholders approved the 2007 Long-Term Incentive Plan (the “2007 Plan”), effective November 21, 2006, to provide incentives to certain eligible employees, directors and consultants. A maximum of 1.4 million shares of the Company’s common stock can be issued under the 2007 Plan in connection with the grant of awards. Awards to purchase common stock have been granted pursuant to the 2007 Plan and are outstanding to various employees, officers, directors, Scientific Advisory Board members and independent distributors at prices between $1.47 and $10.50 per share, with initial vesting periods of one to three years. Awards expire in accordance with the terms of each award and the shares subject to the award are added back to the 2007 Plan upon expiration of the award. The contractual term of stock options granted is generally ten years. As of June 30, 2017, there were stock option awards outstanding, net of awards expired, for the purchase in aggregate of 0.2 million shares of the Company’s common stock. Effective November 21, 2016 no new awards can be granted under the 2007 Plan.

The Company adopted and the shareholders approved the 2010 Long-Term Incentive Plan (the “2010 Plan”), effective September 27, 2010, as amended on August 21, 2014, to provide incentives to certain employees, directors and consultants. A maximum of 1.5 million shares of the Company’s common stock can be issued under the 2010 Plan in connection with the grant of awards. Awards to purchase common stock have been granted pursuant to the 2010 Plan and are outstanding to various employees, officers and directors. Outstanding stock options awarded under the 2010 Plan have exercise prices between $4.41 and $24.71 per share, and vest over one to four year vesting periods. Awards expire in accordance with the terms of each award and the shares subject to the award are added back to the 2010 Plan upon expiration of the award. The contractual term of stock options granted is generally ten years. As of June 30, 2017, there were stock option awards outstanding, net of awards expired, for an aggregate of 0.1 million shares of the Company’s common stock. No new awards will be granted under the 2010 Plan and forfeited or terminated shares will be added to the 2017 Plan pool as described below.

The Company adopted a Performance Incentive Plan effective July 1, 2014 (the "Fiscal 2015 Performance Plan"). The Fiscal 2015 Performance Plan is intended to provide selected employees an opportunity to earn performance-based cash bonuses whose value is based upon the Company’s stock value and to encourage such employees to provide services to the Company and to attract new individuals with outstanding qualifications. The Fiscal 2015 Performance Plan seeks to achieve this purpose by providing for awards in the form of performance share units (the “Units”). No shares will be issued under the Fiscal 2015 Performance Plan. Awards may be settled only with cash and will be paid subsequent to award vesting. The fair value of share-based compensation awards, that include performance shares, are accounted for as liabilities. Vesting for the Units is subject to achievement of both service-based and performance-based vesting requirements. Performance-based vesting occurs in three installments if the Company meets certain performance criteria generally set for each year of a three-year performance period. The service-based vesting criteria occurs in a single installment at the end of the third fiscal year after the awards are granted if the participant has continuously remained in service from the date of award through the end of the third fiscal year. The fair value of these awards is based on the trading price of the Company's common stock and is remeasured at each reporting period date until settlement. The Company adopted separate Performance Incentive Plans effective July 1, 2015 (the "Fiscal 2016 Performance Plan") and July 1, 2016 (the "Fiscal 2017 Performance Plan"). The Fiscal 2016 Performance Plan and Fiscal 2017 Performance Plan include performance-based and service-based vesting requirements and payment terms that are substantially the same as described above the Fiscal 2015 Performance Plan.

The Company adopted and the shareholders approved the 2017 Long-Term Incentive Plan (the “2017 Plan”), effective February 16, 2017 to provide incentives to eligible employees, directors and consultants. The maximum number of shares that can be issued under the 2017 Plan is not to exceed 1,125,000 shares, calculated as the sum of (i) 650,000 shares and (ii) up to 475,000 shares previously reserved for issuance under the 2010 Plan, including shares returned upon cancellation, termination or forfeiture of awards that were previously granted under that plan. Awards expire in accordance with the terms of each award and the shares subject to the award are added back to the 2017 Plan upon expiration of the award.

Stock-Based Compensation

In accordance with accounting guidance for stock-based compensation, payments in equity instruments for goods or services are accounted for by the fair value method. For the fiscal years ended June 30, 2017, 2016 and 2015, stock-based compensation of $2.3 million, $2.0 million and $1.7 million, respectively, was reflected as an increase to additional paid in capital and $0.7 million, $0.7 million and $0.1 million was reflected as an increase to other accrued expenses for the fiscal years ended June 30, 2017, 2016 and 2015, respectively. For the fiscal years ended June 30, 2017, 2016 and 2015, all stock-based compensation was employee related.

At June 30, 2017, there was $4.5 million of unrecognized compensation cost related to nonvested share-based compensation arrangements under the 2010 and 2017 Plans, based on management's estimate of the shares that will ultimately vest. The Company expects to recognize such costs over a weighted-average period of 1.94 years.

Stock Options

There were no stock option grants during the fiscal years ended June 30, 2017, 2016 and 2015. The following is a summary of stock option activity for the years ended June 30, 2017, 2016 and 2015:



	Options (in thousands)		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value (in thousands)
Outstanding at June 30, 2014	735		$	8.23

Granted	—		$	—
Exercised	(22	)	5.04			$	60
Forfeited	(251	)	9.18
Expired or Canceled	—		—
Outstanding at June 30, 2015	462		7.87

Granted	—		$	—
Exercised	(46	)	5.66			$	209
Forfeited	(33	)	17.85
Expired or Canceled	—		—
Outstanding at June 30, 2016	383		7.28

Granted	—		$	—
Exercised	(4	)	4.14			$	17
Forfeited	(62	)	12.64
Expired or Canceled	(7	)	2.45
Outstanding at June 30, 2017	310		6.35		2.71	$	139
Exercisable at June 30, 2017	310		$	6.35	2.71	$	139

Restricted Shares

The following is a summary of restricted shares granted during the years ended June 30, 2017, 2016 and 2015:



Nonvested Shares	Shares (in thousands)		Weighted Average Grant Date Fair Value
Nonvested at June 30, 2014	246		$	17.25

Granted	189		$	5.57
Vested	(75	)	16.57
Forfeited	(110	)	15.54
Nonvested at June 30, 2015	250		9.36
Vested at June 30, 2015	—		—

Granted	60		$	5.94
Vested	(40	)	15.64
Forfeited	(39	)	16.21
Nonvested at June 30, 2016	231		6.24
Vested at June 30, 2016	—		—

Granted	156		$	5.81
Vested	(88	)	8.31
Forfeited	(22	)	10.70
Nonvested at June 30, 2017	277		4.98
Vested at June 30, 2017	—		$	—

The total vesting date fair value of restricted shares that vested during the years ended June 30, 2017, 2016 and 2015 was $0.7 million, $0.4 million and $0.6 million, respectively.

Performance Restricted Stock Units

During the year ended June 30, 2015, the Company awarded performance restricted stock units (the "FY 2015 Performance Stock Units") to its executive officers and senior management (the "Recipients"). Vesting for the FY 2015 Performance Stock Units occurs over three consecutive annual performance periods and is subject to achievement of both service-based and market-based performance vesting requirements. Subject generally to the Recipient's continued service with the Company (the service based requirement), each performance restricted stock unit represents a contingent right for the Recipient to receive, within thirty days after the end of each of three annual performance periods, a distribution of shares of common stock of the Company equal to 0% to 200% of the target number of performance restricted stock units subject to the award for each performance period. The actual number of shares distributed will be based on the Company's total stockholder return ("TSR") performance during the relevant performance period, subject to acceleration upon a change in control of the Company. The vesting for 50% of the target performance restricted stock units is based upon the Company's absolute TSR for the performance period as compared to a matrix of fixed numeric values and the vesting for the other 50% of the target performance restricted stock units is based upon the relative comparison of the Company's TSR to the Vanguard Russell 2000 exchange traded fund TSR. The fair value of the performance restricted stock units will be recognized on a straight-line basis over the requisite service period of the awards, regardless of when, if ever, the market-based performance conditions are satisfied.

During the years ended June 30, 2017 and 2016, the Company awarded additional performance restricted stock units ("FY 2017 Performance Stock Units" and "FY 2016 Performance Stock Units") to its executive officers and senior management. The FY 2017 Performance Stock Units and FY 2016 Performance Stock Units are substantially similar to the FY 2015 Performance Stock Units except that the service-based vesting criteria occurs in a single installment and is achieved at the end of the three year performance period if the participant has continuously remained in service from the date of the award through the end of the performance period.

The fair values of performance restricted stock units granted during the years ended June 30, 2017, 2016 and 2015 were estimated using a Monte Carlo simulation model which included the following assumptions in order to reflect the performance conditions that must be satisfied for the share units to vest:



	June 30, 2017		June 30, 2016		June 30, 2015
Risk-free interest rate	1.49	%	1.31	%	1.07	%
Dividend yield	—	%	—	%	—	%
Expected volatility - Company	62.0	%	55.5	%	54.1	%
Expected volatility - peer company	17.1	%	15.7	%	15.7	%
Total measurement period (years)	2.8		3.0		3.0

The following is a summary of performance restricted stock units granted during the years ended June 30, 2017, 2016 and 2015:



	Number of Units (in thousands)		Weighted Average Grant Date Fair Value
Nonvested at June 30, 2014	—		$	—

Granted	229		$	10.76
Vested	—		—
Forfeited	(114	)	10.76
Nonvested at June 30, 2015	115